Fecal Microbiome Treatment for C. Diff to Face Scrutiny of FDA Panel

(MedPage Today) -- A Bayesian analysis will feature prominently in an FDA advisory board's decision whether to recommend approval of a fecal microbiota transfer (FMT) product for recurrent Clostridium difficile infections, and so may an imbalance...
Source: MedPage Today Public Health - Category: American Health Source Type: news